8-Prenylnaringenin
Based on 1 publication(s) in Google Scholar
8-Prenylnaringenin is an orally active prenyl flavonoid. 8-Prenylnaringenin can be isolated from the hop spike Humulus lupulus. 8-Prenylnaringenin activates the PI3K/Akt pathway and the AMPK pathway, upregulates OXPHOS complexes (II, III, and V) and Sirt1, and reduces ROS production and SOD activity. 8-Prenylnaringenin improves muscle atrophy and obesity and inhibits angiogenesis. 8-Prenylnaringenin exhibits anticancer activity against glioblastoma and colon cancer. 8-Prenylnaringenin also has LH/FSH regulatory activity. 8-prenylnaringenin may be used in bone health research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.63%
- CAS 番号: 53846-50-7
- 分子式: C20H20O5
- 分子量:340.37
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endocrinology Compound Library
HY-L047
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Food-Sourced Compound Library
HY-L094
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
Cell Proliferation Compound Library
HY-L201
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
MedChemExpress（MCE）の使用を引用している文献 8-Prenylnaringenin
MoreAMPK アイソフォーム固有の製品をすべて表示
More
生物活性
|
SIRT1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ishikawa | IC50 |
19.1 μM
Compound: 8-PN
|
Cytotoxicity against human Ishikawa cells after 96 hrs by SRB assay
Cytotoxicity against human Ishikawa cells after 96 hrs by SRB assay
|
[PMID: 28812892] |
| NCI-H460 | IC50 |
3.1 μM
Compound: 7
|
Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C
Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C
|
[PMID: 21275386] |
8-Prenylnaringenin (48 h) exhibits strong inhibitory effect against human colon cancer HCT-116 cells with an IC50 value of 23.83 μg/mL[1].
8-Prenylnaringenin (0.1-10 μM; 0.25-4 h) activates the PI3K/Akt pathway in mouse C2C12 myotubes[2].
8-Prenylnaringenin (10–500 μM; 24 h) shows higher cytotoxicity against human glioblastoma U-118 MG cells (IC50 ≈ 138 μM) than normal BJ fibroblasts (IC50 = 172 μM)[3].
8-Prenylnaringenin (0.001-20 μM; 48 h) reduces reactive oxygen species (ROS) production, SOD activity in MCF-7 breast cancer cells[4].
8-Prenylnaringenin inhibits BME cell invasion with IC50 values ranging from 3 to 10 μM[5].
8-Prenylnaringenin (1-30 μM) inhibits angiogenesis induced by bFGF, VEGF, or a combination of both cytokines in BME cells in a dose-dependent manner[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 (human breast cancer cell line)
-
Concentration:0.01 μM, 1 μM
-
Incubation Time:48 h
-
Result:Upregulated expression of OXPHOS complexes (II, III, V), Sirt1 (sixfold increase at 1 μM).
8-Prenylnaringenin (0.0005%-0.005% wt/wt in high-fat diet; p.o. via mixed diet; 8 weeks) prevents high-fat diet-induced obesity in C57BL/6J male mice by promoting adiponectin secretion and activating the AMPK pathway[6].
8-Prenylnaringenin (126-1260 ppm; p.o. via soy-free diet; 3 months) suppresses serum LH/FSH levels and stimulates uterine weight in ovariectomized Sprague-Dawley rats[7].
8-Prenylnaringenin (1.77 mg/kg; s.c.; daily; 10 weeks) does not improve biomechanical properties or bone mineral density of lumbar vertebrae and femora in ovariectomized Sprague-Dawley rats[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male, 230-290 g initial weight, 5-week-old) fed with high-fat diet[6].
-
Dosage:0.0005% wt/wt, 0.005% wt/wt 8-PN in high-fat diet
-
Administration:Oral administration via mixed high-fat diet; 8 weeks
-
Result:Prevented high-fat diet-induced body weight gain and fat accumulation in WAT.
Reduced liver total lipid and triglyceride levels in the liver.
Inhibitd ALT activity.
Promoted AMPK phosphorylation.
Regulated SREBP-1 and PGC-1α expression via AMPK activation.
化学情報
-
CAS 番号 53846-50-7
-
性状 Solid
-
分子量 340.37
-
分子式 C20H20O5
-
Color White to off-white
-
SMILES
O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
DMSO : 100 mg/mL (293.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Koosha S, et al. Antiproliferative and apoptotic activities of 8-prenylnaringenin against human colon cancer cells. Life Sci. 2019 Jul 3:116633. [Content Brief]
[2]. Mukai R, et al. 8-Prenylnaringenin promotes recovery from immobilization-induced disuse muscle atrophy through activation of the Akt phosphorylation pathway in mice. Am J Physiol Regul Integr Comp Physiol. 2016 Dec 1;311(6):R1022-R1031. [Content Brief]
[3]. Stompor M, et al. In Vitro Effect of 8-Prenylnaringenin and Naringenin on Fibroblasts and Glioblastoma Cells-Cellular Accumulation and Cytotoxicity. Molecules. 2017 Jun 30;22(7). [Content Brief]
[4]. Blanquer-Rosselló MM, et al. Effect of xanthohumol and 8-prenylnaringenin on MCF-7 breast cancer cells oxidative stress and mitochondrial complexes expression. J Cell Biochem. 2013 Dec;114(12):2785-94. [Content Brief]
[5]. Pepper MS, et al. 8-prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. J Cell Physiol. 2004 Apr;199(1):98-107. [Content Brief]
[6]. Okada F, et al. 8-Prenylnaringenin suppresses obesity in high-fat diet-fed C57BL/6J mice via adiponectin secretion. J Clin Biochem Nutr. 2025 Jul;77(1):64-73. [Content Brief]
[7]. Christoffel J, et al. Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment. J Endocrinol. 2006 Mar;188(3):397-405. [Content Brief]
[8]. Hoffmann DB, et al. Effects of 8-Prenylnaringenin and Whole-Body Vibration Therapy on a Rat Model of Osteopenia. J Nutr Metab. 2016;2016:6893137. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9380 mL | 14.6899 mL | 29.3798 mL | 73.4495 mL |
| 5 mM | 0.5876 mL | 2.9380 mL | 5.8760 mL | 14.6899 mL | |
| 10 mM | 0.2938 mL | 1.4690 mL | 2.9380 mL | 7.3449 mL | |
| 15 mM | 0.1959 mL | 0.9793 mL | 1.9587 mL | 4.8966 mL | |
| 20 mM | 0.1469 mL | 0.7345 mL | 1.4690 mL | 3.6725 mL | |
| 25 mM | 0.1175 mL | 0.5876 mL | 1.1752 mL | 2.9380 mL | |
| 30 mM | 0.0979 mL | 0.4897 mL | 0.9793 mL | 2.4483 mL | |
| 40 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.8362 mL | |
| 50 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4690 mL | |
| 60 mM | 0.0490 mL | 0.2448 mL | 0.4897 mL | 1.2242 mL | |
| 80 mM | 0.0367 mL | 0.1836 mL | 0.3672 mL | 0.9181 mL | |
| 100 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.7345 mL |
Powered by Bioz